Literature DB >> 15709009

Cellular and humoral immunity following Snow Mountain virus challenge.

Lisa Lindesmith1, Christine Moe, Jacques Lependu, Jeffrey A Frelinger, John Treanor, Ralph S Baric.   

Abstract

Little is known about the immune response to noroviruses. To elucidate the immunobiology of norovirus infection in humans, 15 volunteers were challenged with Snow Mountain virus (SMV), a genogroup 2 norovirus. We assessed the cellular and humoral immune response and infection by analyzing stool, serum, saliva, and peripheral blood mononuclear cell (PBMC) responses pre- and postchallenge. In contrast to Norwalk virus (NV), SMV infection was not dependent upon blood group secretor status. Nine of 15 volunteers were infected and showed a >/=4-fold increase over the prechallenge anti-SMV serum immunoglobulin G (IgG) titer, mostly subclass IgG1. Although serum IgG elicited by SMV infection was cross-reactive with Hawaii virus (HV), another genogroup 2 norovirus, salivary IgA was less cross-reactive. Neither SMV-elicited serum IgG nor salivary IgA cross-reacted with NV, a genogroup 1 norovirus. Significant increases in serum gamma interferon (IFN-gamma) and IL-2, but not IL-6 or IL-10, were noted on day 2 postchallenge. For the majority of volunteers, both infected and uninfected, PBMCs stimulated with norovirus virus-like particles secreted IFN-gamma and other Th1 cytokines, suggesting previous norovirus exposure in most volunteers. Like the IgG antibodies, the SMV-activated T cells were cross-reactive with HV but not NV. IFN-gamma production was dependent upon CD4(+) cells, consistent with a predominant, but not exclusive, Th1 response. To our knowledge, this is the first report characterizing T-cell and cytokine responses following live norovirus challenge.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15709009      PMCID: PMC548455          DOI: 10.1128/JVI.79.5.2900-2909.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein.

Authors:  X Jiang; M Wang; D Y Graham; M K Estes
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Transmission of acute infectious nonbacterial gastroenteritis to volunteers by oral administration of stool filtrates.

Authors:  R Dolin; N R Blacklow; H DuPont; S Formal; R F Buscho; J A Kasel; R P Chames; R Hornick; R M Chanock
Journal:  J Infect Dis       Date:  1971-03       Impact factor: 5.226

3.  Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers.

Authors:  R G Wyatt; R Dolin; N R Blacklow; H L DuPont; R F Buscho; T S Thornhill; A Z Kapikian; R M Chanock
Journal:  J Infect Dis       Date:  1974-06       Impact factor: 5.226

4.  Immunoglobulin M antibody test to detect genogroup II Norwalk-like virus infection.

Authors:  J P Brinker; N R Blacklow; X Jiang; M K Estes; C L Moe; J E Herrmann
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

5.  Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults.

Authors:  P C Johnson; J J Mathewson; H L DuPont; H B Greenberg
Journal:  J Infect Dis       Date:  1990-01       Impact factor: 5.226

6.  Application of PCR to detect Norwalk virus in fecal specimens from outbreaks of gastroenteritis.

Authors:  C L Moe; J Gentsch; T Ando; G Grohmann; S S Monroe; X Jiang; J Wang; M K Estes; Y Seto; C Humphrey
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

7.  Detection by immune electron microscopy of the Snow Mountain agent of acute viral gastroenteritis.

Authors:  R Dolin; R C Reichman; K D Roessner; T S Tralka; R T Schooley; W Gary; D Morens
Journal:  J Infect Dis       Date:  1982-08       Impact factor: 5.226

8.  Clinical immunity in acute gastroenteritis caused by Norwalk agent.

Authors:  T A Parrino; D S Schreiber; J S Trier; A Z Kapikian; N R Blacklow
Journal:  N Engl J Med       Date:  1977-07-14       Impact factor: 91.245

9.  Rhinovirus-induced interferon-gamma and airway responsiveness in asthma.

Authors:  G Daniel Brooks; Kim A Buchta; Cheri A Swenson; James E Gern; William W Busse
Journal:  Am J Respir Crit Care Med       Date:  2003-08-19       Impact factor: 21.405

10.  Presentation and binding affinity of equine infectious anemia virus CTL envelope and matrix protein epitopes by an expressed equine classical MHC class I molecule.

Authors:  Travis C McGuire; Steven R Leib; Robert H Mealey; Darrilyn G Fraser; David J Prieur
Journal:  J Immunol       Date:  2003-08-15       Impact factor: 5.422

View more
  107 in total

1.  Asymptomatic norovirus infection in Mexican children.

Authors:  Coralith García; Herbert L DuPont; Kurt Z Long; Jose I Santos; GwangPyo Ko
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

Review 2.  Murine norovirus: a model system to study norovirus biology and pathogenesis.

Authors:  Christiane E Wobus; Larissa B Thackray; Herbert W Virgin
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Characterization of emerging GII.g/GII.12 noroviruses from a gastroenteritis outbreak in the United States in 2010.

Authors:  Sayaka Takanashi; Qiuhong Wang; Ning Chen; Quan Shen; Kwonil Jung; Zhenwen Zhang; Masaru Yokoyama; Lisa C Lindesmith; Ralph S Baric; Linda J Saif
Journal:  J Clin Microbiol       Date:  2011-07-13       Impact factor: 5.948

4.  Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues.

Authors:  Samer S El-Kamary; Marcela F Pasetti; Paul M Mendelman; Sharon E Frey; David I Bernstein; John J Treanor; Jennifer Ferreira; Wilbur H Chen; Richard Sublett; Charles Richardson; Robert F Bargatze; Marcelo B Sztein; Carol O Tacket
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

5.  Long-term inactivation study of three enteroviruses in artificial surface and groundwaters, using PCR and cell culture.

Authors:  A M de Roda Husman; W J Lodder; S A Rutjes; J F Schijven; P F M Teunis
Journal:  Appl Environ Microbiol       Date:  2008-12-12       Impact factor: 4.792

6.  Antibody responses to norovirus genogroup GI.1 and GII.4 proteases in volunteers administered Norwalk virus.

Authors:  Nadim J Ajami; Meagan A Barry; Berenice Carrillo; Zana Muhaxhiri; Frederick H Neill; B V Venkataram Prasad; Antone R Opekun; Mark A Gilger; David Y Graham; Robert L Atmar; Mary K Estes
Journal:  Clin Vaccine Immunol       Date:  2012-10-03

7.  Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge.

Authors:  Anna D LoBue; Joseph M Thompson; Lisa Lindesmith; Robert E Johnston; Ralph S Baric
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

8.  Heterotypic humoral and cellular immune responses following Norwalk virus infection.

Authors:  Lisa C Lindesmith; Eric Donaldson; Juan Leon; Christine L Moe; Jeffrey A Frelinger; Robert E Johnston; David J Weber; Ralph S Baric
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

9.  Kinetics of transmission, infectivity, and genome stability of two novel mouse norovirus isolates in breeding mice.

Authors:  Jennifer A Kelmenson; Darcy P Pomerleau; Stephen Griffey; Weidong Zhang; Michele J Karolak; James R Fahey
Journal:  Comp Med       Date:  2009-02       Impact factor: 0.982

10.  Herd immunity to GII.4 noroviruses is supported by outbreak patient sera.

Authors:  Jennifer L Cannon; Lisa C Lindesmith; Eric F Donaldson; Lauryn Saxe; Ralph S Baric; Jan Vinjé
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.